A clinical study investigating the pharmacokinetic interaction between NN703 (tabimorelin), a potential inhibitor of CYP3A4 activity, and midazolam, a CYP3A4 substrate

被引：0
|
作者：
Milan Zdravkovic
Anette K. Olsen
Tina Christiansen
Rainer Schulz
Mitchell E. Taub
Mikael S. Thomsen
Michael H. Rasmussen
Mapoko M. Ilondo
机构：
[1] Research and Development,Novo Nordisk A/S
[2] Department of Clinical Drug Development,Novo Nordisk A/S
[3] Quintiles Innovex (Biodesign),undefined
来源：
European Journal of Clinical Pharmacology | 2003年 / 58卷
关键词：
CYP3A4; Interaction; Midazolam; NN703; Clinical study;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：683 / 688
页数：5
相关论文
共 50 条
  • [41] Effects of metronidazole on hepatic CYP3A4 activity
    Haas, CE
    Kaufman, DC
    DiCenzo, RC
    PHARMACOTHERAPY, 2001, 21 (10): : 1192 - 1195
  • [42] Characterization of the modulation of the CYP3A4 activity by Efavirenz
    Hariparsad, N
    Nallani, SC
    Desai, PB
    DRUG METABOLISM REVIEWS, 2003, 35 : 79 - 79
  • [43] Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole
    Neuvonen, PJ
    Kantola, T
    Kivistö, KT
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 63 (03) : 332 - 341
  • [44] CYP3A4 phenotyping with midazolam to predict sunitinib exposure.
    van Erp, Nielka P.
    de Wit, Djoeke
    Sparreboom, Alex
    den Hartigh, Jan
    den Hollander, Margret
    Konig-Quartel, Jacqueline M. C.
    Hessing, Trees
    Guchelaar, Henk-Jan
    Gelderblom, Hans
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [45] Genetic epidemiology of induced CYP3A4 activity
    Rahmioglu, Nilufer
    Heaton, James
    Clement, Gail
    Gill, Raj
    Surdulescu, Gabriela
    Zlobecka, Karolina
    Hodgkiss, Dylan
    Ma, Yongmin
    Hider, Robert C.
    Smith, Norman W.
    Ahmadi, Kourosh R.
    PHARMACOGENETICS AND GENOMICS, 2011, 21 (10): : 642 - 651
  • [46] Effect of NIPRISAN® on CYP3A4 activity in vitro
    Bulus Adzu
    Collen Masimirembwa
    Kudirat Bola Mustapha
    Roslyn Thelingwani
    Rukaiyatu Abdullahi Kirim
    Karniyus Shingu Gamaniel
    European Journal of Drug Metabolism and Pharmacokinetics, 2015, 40 : 115 - 118
  • [47] Evaluation of the effect of aprepitant on CYP3A4 activity using midazolam as a probe.
    Majumdar, A
    McCrea, J
    Busillo, J
    Panebianco, D
    Dru, J
    Constanzer, M
    Goldberg, MR
    Murphy, G
    Gottesdiener, K
    Blum, R
    Lates, C
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (02) : P6 - P6
  • [48] Influenza immunization and CYP3A4 activity.
    Hayney, MS
    Hammes, RJ
    Fine, JP
    Bianco, JA
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (02) : P16 - P16
  • [49] Drug-drug interaction between tamsulosin and diltiazem, a moderate CYP3A4 inhibitor
    Byeon, Ji-Yeong
    Park, Jung-In
    Jang, Choon-Gon
    Lee, Seok-Yong
    PHARMACOTHERAPY, 2012, 32 (10): : E238 - E239
  • [50] NEW TOOLS TO DIFFERENTIATE CYP3A4 AND CYP3A5 ACTIVITY
    Li, Xiaohai
    Kamenecka, Theodore M.
    Jeso, Valer
    Micalizio, Glen
    Heyward, Scott
    Walker, Gregory S.
    Cameron, Michael D.
    DRUG METABOLISM REVIEWS, 2015, 47 : 70 - 70
12345